Worldwide shipping Reward points on every review 100% Quality Guarantee Safe and Secure Payment
Our Category
Manufacturers

Superdrol/Methyldrostanolone/Methasterone

Androgenic Rating = 20

Anabolic Rating = 400

Estrogenic Activity = none

Progestational Activity = no data available

Chemical Name(s): 2a,17a-dimethyl-5a-androst-3-one-17b-ol 2a,17a-dimethyl-etiocholan-3-one-17b-ol

Chemical Formula: C21H34O2

Molecular Weight: 318

Oral Bioavailability: Estimated at 50%

AR Binding Affinity: NA

SHBG Binding Affinity: High

Half Life: ~8 hours

Legal Status (US): Not listed as a controlled substance

Average Dose: 10-30mg/day standalone 5-10mg/day when stacked

Methyldrostanolone, also known as methasteron, is a potent oral anabolic steroid that was never sold as a prescription drug. In structure, this steroid is a close derivative of drostanolone (Masteron ). The only difference in this case is the addition of a c-17 alpha methyl group, a modification that gives this steroid high oral bioavailability. The two agents remain very comparable, however. Both methyldrostanolone and drostanolone are non-aromatizable, so there is no difference in the estrogenicity of these two steroids , and both steroids retain favorable anabolic to androgenic ratios. Lab assays do put Superdrol ahead here, however, showing it to possess 4 times the anabolic potency of oral methyltestosterone while displaying only 20% of the androgenicity (a 20:1 ratio, compared to 3:1). The exact real-world relevance of these figures remains to be seen, however. Methyldrostanolone is favored by athletes for its moderate anabolic properties, which are usually accompanied by fat loss and minimal androgenic side effects.

History

Methyldrostanolone was first described in 1959. This steroid was developed by the international pharmaceuticals giant Syntex, alongside such other well known anabolic agents as drostanolone propionate and Oxymetholone. Unlike drostanolone and oxymetholone, however, this steroid (at least in its basic form) was never released as a medicinal product. It was only sold for a brief period of time as a modified hormone called dimethazine. Dimethazine is made from two molecules of Methyldrostanolone that are bonded together, which are later metabolically separated to yield free Methyldrostanolone. So while technically Methyldrostanolone itself was never sold as a prescription agent, we can say that the drug was one utilized medicinally.OtherWise, the methyldrostanolone molecule Methyldrostanolone remained an obscure research steroid only, and was never itself approved for use in humans. Methyldrostanolone was released in early 2005 as an over the counter "grey market" anabolic steroid in the United States. The drug was being sold without restrictions as a nutritional supplement product, barring some minimum age disclaimers by the manufacturer. No State or Federal laws identify this drug as an anabolic steroid, which remove the legalities associated with being a Class III controlled substance like other steroids. This is simply due to the fact that methyldrostanolone was not in commerce at the time such laws were written, and was unknown to lawmakers. It was never legal to sell as a dietary supplement, however, and in late 2005 the FDA angrily acknowledged methyldrostanolone was being sold on the sports supplement market. In early 2006, the FDA sent letters to the manufacturer and a distributor demanding it be pulled from commerce. Superdrol has since been discontinued.

Characteristics

Methyldrostanolone is a C-17 alpha alkylated steroid, originally developed by the American pharmaceutical company Syntex. This steroid is already active and does not require conversion. Methyldrostanolone is the 17aa version of the injectable steroid drostanolone (Masteron). This extra methylation makes this steroid about 3-4x more anabolic than Masteron, and slightly more anabolic than oxandrolone (Anavar ). Due to the dimethylation, the toxicity of methyldrostanolone is greater than most other oral steroids . There have been many reported cases of heptatoxicity with this compound. (1-3) Despite the fact that methyldrostanolone is a DHT derivative and cannot convert to estrogen, some users have still reported gyno like symptoms during or after a cycle. This effect is likely related to the strong SHBG binding effect and increase in freely circulating estrogen (and testosterone) from SHBG. Gyno symptoms may also be related to the fact that methldrostanolone lacks a strong DHT metabolite to antagonize the effects of estrogen (while also having a relatively low intrinsic androgenic value). Having a fairly low androgenic value will mean that methyldrostanolone will be light on the hairline for most men. However those susceptible to male pattern baldness may still noticed accelerated hair loss during a cycle. Because of the di-methylation, methlydrostanolone is considerably more resistant to breakdown, thus more potent per mg than most other steroids. However this makes it more liver toxic than other single methylated 17aa orals. Negative effects on the liver generally manifest as a condition known as reversible cholestasis. This is essentially a slowing or complete blockage of bile acids from the liver. Immediate signs of compromised liver function included reduced appetite and general sickness, which will soon be accompanied by yellowing of the eyes (jaundice), excessive itchiness and very dark urine. If these effects are noticed, methyldrostanolone should be discontinued immediately. Because the effects on the liver it is very important to use a liver protecting supplement during any methyldrostanolone cycle. If not using a supplement to protect your liver, methyldrostanolone should never be used any longer than 2 weeks, with a maximum cycle length of 4 weeks with liver protection. Other reversible side effects from methyldrostanolone may include increased blood pressure, reduced HDL cholesterol and lower back pumps. Results wise, users should expect extreme strength increases and weight gain in a relatively short 2-4 week period. Weight gain upwards of 20lbs in 4 weeks is not unheard of with this incredibly potent compound. Although subcutaneous water gain would be minimal, intramuscular water retention should be expected. This is due to inhibition of 11b-hydroxylase and build-up of mineralcorticoids which encourage salt and water retention within the muscles. The most obvious physical effects will be improved vascularity, aggressive muscular pumps, and oily skin. While methyldrostanolone can stack well with most other steroids, it should never be stacked with another methylated (17aa) steroid.

Side Effects

Methyldrostanolone is not aromatized by the body, and is not measurably estrogenic. An anti-estrogen is not necessary when using this steroid, as gynecomastia should not be a concern even among sensitive individuals. Since estrogen is the usual culprit with water retention, methyldrostanolone instead produces a lean, quality look to the physique with no fear of excess subcutaneous fluid retention. This makes it a favorable steroid to use during bulking or cutting cycles, when water and fat retention are major concerns.

Despite the fact that methyldrostanolone is a DHT derivative and cannot convert to estrogen, some users have still reported gyno like symptoms during or after a cycle. This effect is likely related to the strong SHBG binding effect and increase in freely circulating estrogen (and testosterone) from SHBG. Gyno symptoms may also be related to the fact that methldrostanolone lacks a strong DHT metabolite to antagonize the effects of estrogen (while also having a relatively low intrinsic androgenic value).

Having a fairly low androgenic value will mean that methyldrostanolone will be light on the hairline for most men. However those susceptible to male pattern baldness may still noticed accelerated hair loss during a cycle.

Because of the di-methylation, methlydrostanolone is considerably more resistant to breakdown, thus more potent per mg than most other steroids. However this makes it more liver toxic than other single methylated 17aa orals. It is believed that this is the cause for why some users report lethargy. Negative effects on the liver generally manifest as a condition known as reversible cholestasis. This is essentially a slowing or complete blockage of bile acids from the liver. Immediate signs of compromised liver function included reduced appetite and general sickness, which will soon be accompanied by yellowing of the eyes (jaundice), excessive itchiness and very dark urine. If these effects are noticed, methyldrostanolone should be discontinued immediately.

Other reversible side effects from methyldrostanolone may include increased blood pressure, reduced HDL cholesterol and lower back pumps.

Administration

Methydrostanolone was never approved for use in humans. Prescribing guidelines are unavailable. An effective dosage of methyldrostanolone for physique or performance-enhancing purposes seems to begin in the range of 10-20 mg per day, taken for no longer than 6 weeks. At this level it seems to impart a measurable muscle-building effect, which is usually accompanied by fat loss and increased definition. Don't expect to gain 30 pounds on this agent (its name, which is short for "Super Anadrol " is more marketing than reality), but many do walk away with more than 10 pounds of solid muscle gain when using this agent alone. In determining an optimal daily dosage, some do find the drug to be measurably more effective when venturing up to the 30 mg range. Potential hepatotoxicity should definitely be taken into account with such use, however.

References

Cholestatic Jaundice and IgA Nephropathy Induced by OTC Muscle Building Agent Superdrol.

Beata Jasiurkowski MD, et al.

The American Journal of Gastroenterology (2006) 101, 2659-2662;

Severe Cholestasis and Renal Failure Associated with the Use of the Designer Steroid Superdrol (Methasteron): A Case Report and Literature Review

John Nasr and Jawad Ahmad

Digestive Diseases and Sciences

Methasteron-Associated Cholestatic Liver Injury: Clinicopathologic Findings in 5 Cases”

Neeral L. et al.

Clinical Gastroenterology and Hepatology, Volume 6, Issue 2, February 2008, Pages 255-258

Identification of drostanolone and 17-methyldrostanolone metabolites produced by cryopreserved human hepatocytes”

Julie Gauthier, Danielle Goudreault, Donald Poirier and Christiane Ayotte

Steroids; Volume 74, Issue 3, March 2009, Pages 306-314

19.08.2020